Genialis
Genialis is a precision oncology company that builds AI foundation models and biomarker discovery software for biopharma and diagnostics, using its Supermodel trained on over one billion RNA-seq data points to predict patient response to cancer therapies.
- Company typePrivate
- Founded2013
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Genialis does
Genialis is a Boston-based computational precision oncology company that develops AI foundation models and biomarker discovery software for biopharmaceutical sponsors and diagnostic firms. Its flagship technology, the Genialis Supermodel, is an AI foundation model of cancer biology trained on more than one billion RNA-sequencing data points from globally diverse patient populations, mapping high-dimensional transcriptomic data into interpretable "biomodules" that represent oncologic hallmarks. Built on top of the Supermodel, the company offers Genialis Expressions (cloud-based bioinformatics for multiomics data management), the Genialis Precision Medicine SDK (a Python toolkit for ML-ready data preparation, covered by patent-pending preprocessing), and ResponderID, a clinical biomarker discovery platform. Specialized biomarker sub-products — krasID, adcID, the DDR Biomarker, the Xerna TME Panel, and the recently launched BioBridge for China-to-Western clinical data translation — extend the platform into specific therapeutic response prediction use cases.
The company monetizes through enterprise SaaS subscriptions (annual billing, Net 30 terms) and professional services for custom predictor development, biomarker assay commercialization, and clinical trial analysis. Customers include Roche, Tempus, Debiopharm, Exact Sciences, Cancer Research Horizons, OncXerna Therapeutics, Hotspot Therapeutics, Inhibrx, Sutter Health, and Baylor College of Medicine, spanning biopharma, diagnostics, academic translational research, and health systems. Genialis operates from Boston, Houston, and Ljubljana, where its wholly-owned Slovenian subsidiary Genialis d.o.o. houses much of the bioinformatics engineering talent. The company has raised approximately $15.3M in disclosed funding across a 2017 seed round and a March 2023 Series A co-led by Taiwania Capital and Debiopharm Innovation Fund, and maintains ISO/IEC 27001, HIPAA, and GDPR compliance to meet enterprise and regulatory procurement requirements.
Genialis firmographics
Firmographics- Name
- Genialis
- Legal name
- Genialis, Inc.
- Website
- https://genialis.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genialis is a precision oncology company that builds AI foundation models and biomarker discovery software for biopharma and diagnostics, using its Supermodel trained on over one billion RNA-seq data points to predict patient response to cancer therapies.
- Ownership category
- akta.pro rank
Genialis industry classification
Industry- Product category
- Precision Oncology Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (51321), Custom Computer Programming Services (541511)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Genialis is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Genialis business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software Licensing (SaaS): Genialis Expressions and related software offered as subscription-based cloud software. Customers subscribe to access bioinformatics pipelines, data management, and analysis tools. Licensing of biomarkers and predictors for clinical and translational research.
- Professional Services: Custom predictor development, biomarker assay development, and clinical trial analysis services. Collaboration with biopharma and diagnostic firms for clinical trial analysis and biomarker assay commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription with custom pricing based on scope and usage |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Genialis product offering
Product offeringCore offering
Genialis builds and sells a precision oncology AI platform centered on the Genialis Supermodel — an AI foundation model of cancer biology trained on more than one billion RNA-sequencing data points. The platform packages multiomics data infrastructure (Expressions), a Python ML-prep SDK (GPM), and a clinical biomarker discovery platform (ResponderID), along with specialized biomarker sub-products (krasID, adcID, DDR Biomarker, BioBridge, Xerna TME Panel). It is sold via subscription licensing and professional services to pharmaceutical sponsors and diagnostic companies for patient stratification, treatment response prediction, and regulatory submission support.
Product overview
Genialis is a precision oncology company offering a platform architecture centered on the Genialis Supermodel, an AI foundation model trained on over one billion RNA-sequencing data points that maps gene expression into biomodules representing key oncologic hallmarks. The platform comprises core components including Genialis Expressions (cloud-based bioinformatics for multiomics data processing), the Genialis Precision Medicine SDK (Python-based ML preparation tools), and ResponderID (clinical biomarker discovery platform). Specialized biomarker sub-products built on this architecture include krasID for KRAS inhibitor response prediction, adcID for ADC therapeutics response, and the DDR Biomarker for DNA Damage Response. The portfolio also includes BioBridge for cross-population translational analysis and the Xerna TME Panel for tumor microenvironment classification. The platform serves biopharma and diagnostic partners across the drug development lifecycle from discovery through clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- ResponderID: Clinical biomarker discovery platform for predicting patient response to therapies
- Genialis Supermodel
- Genialis Expressions
- Genialis Precision Medicine SDK
- krasID
- adcID
- DDR biomarker
- BioBridge
Products and services
- Genialis Supermodel AI foundation model of cancer biology that transforms high-dimensional transcriptomic data into interpretable biological features called biomodules, enabling prediction of patient response to therapies. Sold as a platform component underpinning Genialis' biomarker sub-products.
- Genialis Expressions Cloud-based bioinformatics platform for primary analysis and management of genomic, transcriptomic, and epigenomic sequencing data, providing standardized annotation, validated pipelines, and built-in QC/QA workflows. Sold via SaaS subscription with browser-based GUI and Python ReSDK access.
- Genialis Precision Medicine SDK (GPM) Production-ready Python SDK for preparing sequencing data for machine learning applications, with built-in data normalization, batch effect detection and correction, and a framework for training new predictors. Sold as a developer-facing software component with documented APIs.
- Genialis ResponderID Clinical biomarker discovery platform that defines, models, and validates actionable biomarkers to optimally position novel drugs and accelerate clinical development. Sold via SaaS subscription and custom professional services engagements to biopharma sponsors and diagnostic partners.
- Genialis krasID RNA-based biomarker framework built on the Supermodel for predicting patient response to KRAS inhibitors, applying biology-driven machine learning to personalize KRAS-targeted therapeutics.
- Genialis adcID RNA-based survival model built on the Supermodel for predicting response to trastuzumab deruxtecan (T-DXd, Enhertu) in HER2-expressing breast cancer, identifying transcriptomic patterns linked to DNA damage response, stress signaling, and hormone regulation.
- DDR Biomarker DNA Damage Response biomarker for predicting response to WEE1 inhibitors and other DDR-targeted therapies. Developed in collaboration with Debiopharm.
- BioBridge Platform that translates oncology clinical trial data from Chinese patient populations into biomarker-ready assets for Western regulatory submissions, using the Supermodel to predict response patterns and support FDA and EMA approvals.
- Xerna TME Panel Pan-cancer RNA-based investigational assay that classifies tumors into four microenvironment subtypes using approximately 100 genes involved in angiogenesis and tumor immune biology, designed to predict patient response to angiogenic- and immune-targeted therapies. Co-developed with OncXerna Therapeutics.
Quantifiable outcome
- Identified transcriptomic patterns associated with T-DXd response beyond target expression, revealing biological programs linked to DNA damage response, stress signaling, and hormone regulation
- +2 more outcomes
Companies that use Genialis
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles3 records
Genialis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Genialis partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- TempuscoreCollaboration on ASCO 2026 research for biology-informed predictive modeling and resistance monitoring in metastatic breast cancer treated with T-DXd. Combined multimodal real-world data from Tempus with Genialis Supermodel.
- DebiopharmcoreDeploying Genialis software to support AI-driven biomarker discovery. Focus on privacy and data management practices. Collaboration includes DDR biomarker for WEE1 inhibitor response.
- Cancer Research HorizonscoreCollaboration to develop AI-driven patient classifiers using high-quality and clinically relevant data for disease modeling. Data-sharing partnership leveraging Cancer Research UK's resources.
- OncXerna TherapeuticscoreCo-development of Xerna TME Panel - pan-cancer RNA-based assay for predicting therapeutic response. Collaboration on multiple posters at AACR, ESMO, SITC. Joint biomarker development for tumor microenvironment classification.
- Exact SciencescorePartner collaboration on biomarker development and patient stratification for precision oncology.
- RochecorePartner collaboration on biomarker analysis and clinical development. Global partnership announced at ASHG 2018.
- Sutter HealthminorPartner collaboration on clinical data and biomarker validation.
- Hotspot TherapeuticsminorPartner collaboration on biomarker discovery.
- Baylor College of MedicineminorPartnership on next generation sequencing and biomarker research. Collaboration announced October 2017.
- InhibrxminorSelected Genialis ResponderID for clinical optimization study of INBRX-109. Evaluation of ML technology platform for potential biomarker discovery.
- LexogenminorProject partner in EUREKA GenExpress project (2018-2020) for developing methods to analyze QuantSeq data and CLIP data (protein-RNA interactions).
- BioLab (University of Ljubljana)minorAcademic partnership for joint research on survival analysis and gene ranking methods. Award-winning collaboration resulting in Marco Ramoni Best Paper Award at AIME 2023.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Genialis competitors and assessment
Company assessmentBroad incumbents
- Insitro: AI-driven drug discovery and target identification platform combining ML with functional genomics; comparable as a capital-intensive AI precision-medicine player pursuing pharma collaborations.
- Exscientia: AI-driven precision medicine company with an emphasis on patient-derived data and biomarker-driven drug design; overlaps with Genialis's biology-first AI approach to oncology R&D.
- Recursion Pharmaceuticals: Large-scale AI drug discovery platform combining high-throughput biology with foundation models; broader scope than Genialis but operates in the same AI-for-precision-medicine category serving biopharma.
- Foundation Medicine (Roche): Molecular diagnostics leader in comprehensive genomic profiling and companion diagnostics for oncology; Genialis is both a peer in biomarker-driven pharma services and a partner via Roche collaborations.
Direct peers
- Tempus AI: AI-driven precision medicine company combining multimodal real-world clinical and molecular data for oncology; Genialis and Tempus collaborate (ASCO 2026 T-DXd poster) and compete for the same biomarker-driven pharma R&D spend.
- SOPHiA GENETICS: AI-powered genomics and clinical informatics platform serving biopharma and hospitals with biomarker and genomic interpretation workflows; directly comparable to Genialis Expressions + ResponderID as a SaaS bioinformatics/biomarker stack.
- Owkin: AI biotech combining multimodal patient data and foundation models to develop biomarkers and precision therapeutics; competes with Genialis in AI-driven biomarker discovery for biopharma.
- Personalis: Cancer genomics company providing molecular diagnostic assays and biomarker services to biopharma, with a focus on immuno-oncology; overlaps with Genialis's RNA-based biomarker and patient stratification offerings.
- PathAI: AI pathology and biomarker company building foundation models for tissue-based diagnostics and pharma biomarker discovery; comparable as an AI foundation-model-driven biomarker partner for biopharma.
Emerging players
- Lantern Pharma: AI-driven oncology drug development company using machine learning and biomarker signatures to repurpose and develop oncology therapies; comparable as a smaller AI-oncology player pursuing biomarker-driven pharma partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Genialis social profiles
Digital presenceGenialis compliance and trust
Trust signalCompliance4 records
Genialis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genialis leadership team
Management profileNumber of profiles
Profiles5 records
Genialis subsidiaries and ownership
Company hierarchySubsidiaries1 record
Genialis funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genialis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genialis
What does Genialis do?
Genialis builds and sells a precision oncology AI platform centered on the Genialis Supermodel — an AI foundation model of cancer biology trained on more than one billion RNA-sequencing data points. The platform packages multiomics data infrastructure (Expressions), a Python ML-prep SDK (GPM), and a clinical biomarker discovery platform (ResponderID), along with specialized biomarker sub-products (krasID, adcID, DDR Biomarker, BioBridge, Xerna TME Panel). It is sold via subscription licensing and professional services to pharmaceutical sponsors and diagnostic companies for patient stratification, treatment response prediction, and regulatory submission support.
Is Genialis a public or private company?
Genialis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Genialis founded?
Genialis was founded in 2013. It employs 11 to 50 people.
Where is Genialis based?
Genialis is headquartered in Boston, United States, in the North America region.
How does Genialis make money?
Two revenue lines are on record. Software Licensing (SaaS) is the primary driver. The others are professional Services.
Who are Genialis's main competitors?
Broad incumbents on record are Insitro, Exscientia, Recursion Pharmaceuticals and Foundation Medicine (Roche). Direct peers are Tempus AI, SOPHiA GENETICS, Owkin, Personalis and PathAI. Lantern Pharma is listed as an emerging player.
Does Genialis have an API?
Yes. Genialis provides APIs for its software components allowing deployment within existing software architectures. Each component (Genialis Expressions, Genialis Supermodel, Genialis Precision Medicine SDK, and Predictors) comes with an API. Genialis Expressions offers both programmatic access via Python-based ReSDK and graphical access via a browser-based user interface. The Genialis Precision Medicine SDK is a production-ready Python SDK for preparing sequencing data for machine learning applications. Developer documentation is at docs.genialis.com.
What industry is Genialis in?
Genialis's product category is Precision Oncology Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 7372.